

FORM PTO-1390
(REV 10-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

1719F US

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/856987

INTERNATIONAL APPLICATION NO.
PCT/US99/28385INTERNATIONAL FILING DATE
01.12.1999 (01 December 1999)PRIORITY DATE CLAIMED
03.12.1998 (03 December 1998)TITLE OF INVENTION USE OF NEUROTROPHIC FACTOR STIMULATORS FOR THE TREATMENT OF
OPHTHALMIC NEURODEGENERATIVE DISEASES

APPLICANT(S) FOR DO/EO/US PANG, lok-hou

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
4. ☒ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 16 below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:

International Search Report
Written Opinion
International Preliminary Examination Report

Express Mail No.
EL587888413US

U.S. APPLICATION NO. 09/856987 <small>(known as 37 CFR 1.53)</small>		INTERNATIONAL APPLICATION NO PCT/US99/28385		ATTORNEY'S DOCKET NUMBER 1719F US	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>				CALCULATIONS PTO USE ONLY <div style="border: 1px solid black; height: 150px; width: 100%;"></div>	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 690.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	14 - 20 =	0	X \$18.00	\$	0
Independent claims	2 - 3 =	0	X \$80.00	\$	0
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$	0
TOTAL OF ABOVE CALCULATIONS =				\$	690.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
SUBTOTAL =				\$	690.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$	690.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	40.00
TOTAL FEES ENCLOSED =				\$	0
				Amount to be refunded:	\$
				charged:	\$ 730.00

a. ☐ A check in the amount of \$_____ to cover the above fees is enclosed.


b. ☒ Please charge my Deposit Account No. 01-0682 in the amount of \$ 730.00 to cover the above fees.
 A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
 overpayment to Deposit Account No. 01-0682. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO

Sally Yeager, R&D Counsel
 Alcon Research, Ltd.
 Mail Code Q-148
 6201 South Freeway
 Fort Worth, TX 76134-2099


 SIGNATURE
 Sally Yeager
 NAME
 32,757
 REGISTRATION NUMBER

**Use of Neurotrophic Factor Stimulators
for the Treatment of Ophthalmic Neurodegenerative Diseases**

5

The present invention relates to the use of neurotrophic factor stimulators to treat ophthalmic neurodegenerative diseases.

10 **Background of the Invention**

Primary open-angle glaucoma (POAG) is a progressive disease leading to optic nerve damage and, ultimately, loss of vision. The cause of this disease has been the subject of extensive studies for many years, but is still not fully understood. Glaucoma results in the neuronal degeneration of the retina and optic nerve head. Even with aggressive medical care and surgical treatment, the disease generally persists causing a gradual loss of retinal neurons (retinal ganglion cells ("RGCs")), a decline of visual function, and ultimately blindness (Van Buskirk et al., *Predicted outcome from hypotensive therapy for glaucomatous optic neuropathy*, Am. J. Ophthalmol., volume 25, pages 636-640 (1993); Schumer et al., *The nerve of glaucoma!*, Arch. Ophthalmol., volume 112, pages 37-44 (1994)).

Several theories have been proposed to elucidate the etiology of glaucoma. One theory suggests that excessive intraocular pressure (in some cases coupled with genetic defects on the optic nerve head, RGC or the optic nerve) disrupts the normal axonal transport along the optic nerve, eventually leading to RGC injury.

Disturbance of axonal transport of the optic nerve hinders traffic of intracellular molecules between the RGC cell soma and its terminal. Among the intracellular molecules of importance are neurotrophic factors. Neurotrophic factors are peptide molecules which

stimulate or otherwise maintain growth of neural tissue. The transport of neurotrophic factors from the brain to the cell body of RGCs is essential to the survival of the RGCs. Deprivation of neurotrophic factors can induce apoptosis of neurons (Raff et al., *Programmed cell death and the control of cell survival: lessons from the nervous system*, Science, volume 262, pages 695-700 (1993)).

Deprivation of neurotrophic factors appears to be a cause of glaucoma-induced RGC apoptosis, as such causal link is supported by a great deal of experimental evidence (see, generally, Anderson et al., *Effect of intraocular pressure on rapid axoplasmic transport in monkey optic nerve*, Invest. Ophthalmol., volume 13, pages 771-783 (1974); Quigley et al., *The dynamics and location of axonal transport blockade by acute intraocular pressure elevation in primate optic nerve*, Invest. Ophthalmol., volume 15, pages 606-616 (1976); Mansour-Robaey et al., *Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells*, Proc. Natl. Acad. Sci. USA, volume 91, pages 1632-1636 (1994); Meyer-Franke et al., *Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture*, Neuron, volume 15, pages 805-819 (1995); and Cui et al., *NT-4/5 reduces naturally occurring retinal ganglion cell death in neonatal rats*, Neuroreport, volume 5, pages 1882-1884 (1994)). Such trophic factors include neurotrophins and other cytokines.

The neurotrophin ("NT") family of peptides include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), NT-3, NT-4/5 and NT-6. They act by binding to neuron surface receptors, such as TrkA, TrkB, TrkC and p75NTR. The Trk receptors are tyrosine kinases. TrkA is selective for NGF, TrkB is selective for both BDNF and NT-4/5, whereas TrkC is selective for NT-3. After binding, the NT-receptor complex is internalized and transported via the axon to the soma. These receptors undergo ligand-induced phosphorylation

and dimerization, and activate a cascade of Ras protein-mediated signal transduction events that affect multiple vital functions of the neuron (Lewin et al., *Physiology of the neurotrophins*, Ann. Rev. Neurosci., volume 19, pages 289-317 (1997); Segal et al., *Intracellular signaling pathways activated by neurotrophic factors*, Ann. Rev. Neurosci., volume 19, pages 463-489 (1996); Ebadi et al., *Neurotrophins and their receptors in nerve injury and repair*, Neurochem Int., volume 30, pages 347-374 (1997); Kaplan et al., *Signal transduction by the neurotrophin receptors*, Curr. Opin. Cell Biol., volume 9, pages 213-221 (1997)). Thus, these receptors play a fundamental role in the regulation of survival and differentiation of developing neurons and contribute to the maintenance of neuronal machinery in adult life.

In the retina, mRNA of both TrkA and TrkB has been observed in RGCs, dopaminergic amacrine cells and the optic nerve ("ON"). Their expression was shown to be highly regulated during neuronal development (see, Jelsma et al., *Different forms of the neurotrophin receptor trkB mRNA predominate in rat retina and optic nerve*, J. Neurobiol., volume 24, pages 1207-1214 (1993); Rickman et al., *Expression of the protooncogene, trk, receptors in the developing rat retina*, Vis. Neurosci., volume 12, pages 215-222 (1995); Ugolini et al., *TrkA, TrkB and p75 mRNA expression is developmentally regulated in the rat retina*, Brain Res., volume 704, pages 121-124 (1995); Cellerino et al., *Brain-derived neurotrophic factor/neurotrophin-4 receptor TrkB is localized on ganglion cells and dopaminergic amacrine cells in the vertebrate retina*, J. Comp. Neurol., volume 386, pages 149-160 (1997)). The TrkB receptor-selective ligands, BDNF and NT-4/5, have been shown to be efficacious for the protection of RGCs. Numerous studies have shown that these NTs not only improve the survival and neurite outgrowth of RGCs in culture, but also significantly reduce axotomy-induced *in vivo* damage of the ON and RGCs, as well as stimulate the growth of axonal branches from regenerating RGCs (see, generally, the Anderson et al.; Quigley et al.; Mansour-Robaey et al.; Meyer-Franke et al.; and

Cui et al. publications cited above). For example, a single intravitreal injection of 5 µg of BDNF prevented the death of the axotomized RGCs when administered during the first five days after injury (Mansour-Robaey et al., above). In contrast with the loss of nearly half of the axotomized RGCs in the untreated retinas, virtually all RGCs were present one week after a single injection of BDNF on Day 0. Messenger RNA expression of BDNF was significantly elevated in the rat RGC layer after ON injury (Gao et al., *Elevated mRNA expression of brain-derived neurotrophic factor in retinal ganglion cell layer after optic nerve injury*, Invest. Ophthalmol. Vis. Sci., volume 38, pages 1840-1847 (1997)), further suggesting the potential importance of this NT in retinal recovery.

In addition to these protective effects against mechanical damage at the retina and/or ON, neurotrophins may also be protective against other forms of neuronal insult. By a yet unknown mechanism (but possibly a suppression of the apoptosis cascade), BDNF protects CNS neurons from glutamate neurotoxicity (Lindholm et al., *Brain-derived neurotrophic factor is a survival factor for cultured rat cerebellar granule neurons and protects them against glutamate-induced neurotoxicity*, Eur. J. Neurosci., volume 5, pages 1455-1464 (1993)); and it has been effective *in vivo* in preventing ischemic cell death in the rat retina (Unoki et al., *Protection of the rat retina from ischemic injury by brain-derived neurotrophic factor, ciliary neurotrophic factor, and basic fibroblast growth factor*, Invest. Ophthalmol. Vis. Sci., volume 35, pages 907-915 (1994)), and hippocampus (Beck et al., *Brain-derived neurotrophic factor protects against ischemic cell damage in the rat hippocampus*, J. Cereb. Blood Flow Metab., volume 14, pages 689-692 (1994)).

Ciliary neurotrophic factor (CNTF) is another trophic factor that supports survival of neurons. It is part of a cytokine family structurally unrelated to neurotrophins. Both CNTF and its receptor are expressed by the Müller glia during retinal neurogenesis and differentiation

(Kirsch et al., *Evidence for multiple, local functions of ciliary neurotrophic factor (CNTF) in retinal development: expression of CNTF and its receptors and in vitro effects on target cells*, J. Neurochem., volume 68, pages 979-990 (1997). It may also be useful in preventing glaucomatous neuropathy, since it prevents lesion-induced death of RGCs (Mey et al.,
5 *Intravitreal injections of neurotrophic factors support the survival of axotomized retinal ganglion cells in adult rats in vivo*, Brain Res., volume 602, pages 304-317 (1993)) and ON axonal degeneration, albeit less effective than BDNF (Weibel et al., *Brain-derived neurotrophic factor (BDNF) prevents lesion-induced axonal die-back in young rat optic nerve*, Brain Res., volume 679, pages 249-254 (1995)).

10 Thus, neurotrophic factors play an ameliorative role in glaucomatous retinopathy, and retinal degeneration in general. These trophic factors, however, are peptide molecules, and are therefore difficult to exploit pharmaceutically due to bioavailability problems generally resident in the pharmaceutical administration of peptides. What are needed, therefore, are non-peptide molecules which stimulate neurotrophic activity in compromised retinal tissues, without the
15 bioavailability problems attendant to the natural peptides.

Several neurotrophic factor stimulators have been reported in the scientific literature, for example, AIT-082 (Graul & Castaner, *AIT-082*, *Drugs of the Future*, volume 22, pages 945-947 (1997)), idebenone (Nabeshima et al., *Oral administration of NGF synthesis stimulators recovers reduced brain NGF content in aged rats and cognitive dysfunction in*
20 *basal-forebrain-lesioned rats*, *Gerontology*, volume 40, supplement 2, pages 46-56 (1994)), ONO-2506 (Matsui et al., *Protective effects of ONO-2506 on neurological deficits and brain infarct volume following 1 week of permanent occlusion of middle cerebral artery in rats*, *Society for Neurosci. Abstracts*, volume 24, page 254 (1998)), NS521 (Gronborg et al., *Neuroprotection by a novel compound, NS521*, *Society for Neurosci. Abstracts*, volume 24,

page 1551 (1998)), CB-1093 (Aimone et al., *The $1\alpha,25(OH)_2D_3$ analog CB-1093 induces nerve growth factor in non-human primate brain*, Society for Neurosci. Abstracts, volume 24, page 292, (1998)) and Clenbuterol (Culmsee et al., *NGF antisense oligonucleotide blocks protective effects of clenbuterol against glutamate-induced excitotoxicity in vitro and focal cerebral ischemia in vivo*, Society for Neurosci. Abstracts, volume 24, page 295 (1998)).

However, nowhere in the art has it been disclosed or suggested to use neurotrophic factor stimulators to treat glaucoma or other ophthalmic neuropathies.

Summary of the Invention

The present invention is directed to compositions and methods for treating glaucomatous neuropathy and retinal degenerative diseases. The compositions and methods comprise neurotrophic factor stimulators for the treatment of compromised or at risk retinal or optic nerve head tissue.







The neurotrophic factor stimulators are compounds which stimulate the production or activity of retinal neurotrophic factors. The stimulation of neurotrophic factors in the eye ameliorates the conditions of glaucomatous neuropathy and other retinal and optic nerve head degenerative diseases.

Preferred compositions and methods are directed to the neurotrophic factor stimulators, AIT-082 (neotrofin) and idebenone.

Detailed Description of the Invention

The present invention is directed to compositions and methods for treating glaucomatous neuropathy and other retinal or optic nerve head degenerative diseases. The compositions comprise one or more neurotrophic stimulator(s) in a pharmaceutically acceptable vehicle.

As used herein, "neurotrophic factor stimulators" refer to those compounds which increase the in situ production or activity of neurotrophic factors in the retina. As used herein, "neurotrophic factor" refers to NGF, BDNF, NT-3, NT-4/5, NT-6, CNTF or other trophic factors which prevent, treat or ameliorate retinal neuropathy. Examples of neurotrophic factor stimulators include: AIT-082 (neotrofin), idebenone, ONO-2506, CB-1093, NS521 ((1-(1-butyl)-4-(2-oxo-1-benzimidazolone) piperidine) SS-701, KT-711 and clenbuterol. The most preferred neurotrophin stimulator of the present invention is AIT-082 (neotrofin). The preceding molecules may be obtained commercially or may be synthesized by methods known to those skilled in the art.



Example 1

The following example demonstrates the protective efficacy of a neurotrophic factor stimulator (propentofylline) against retinal cell insult.

5

Retinal Ganglion Cell Survival Assay:

Techniques for the isolation and culture of RGCs were adapted from those reported by Takahashi N. et al., *Rat retinal ganglion cells in culture*. Exp. Eye Res. volume 53, pages 565-572 (1991). The procedure involved the retrograde labeling of ganglion cells by

injecting a fluorescent dye, Di-I, into the superior colliculi. Two to 4 days later, retina cells were dissociated. Cultured RGCs were identified by sufficient Di-I fluorescence to be observed visually using a fluorescent microscope.

Neonatal, Sprague-Dawley rats, 2-5 days old, were anesthetized by hypothermia, after which, a 2 mm midline opening was made in the scalp just caudal to the traverse sinus. The tip of the injection needle (30 gauge) was inserted 6 mm below the top of the skull, and a 5 µl Di-I solution, containing 3 mg/ml Di-I (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (Molecular Probes, Eugene, OR) in 90% ethanol and 10% dimethylsulfoxide, was injected. The wound was then covered with a drop of Flexible Collodion (Amend Drug & Chemical Co., Irvington, NJ). Rats were returned to their mother after warming and recovery from anesthesia.

Two to 4 days after Di-I injection, rats were anesthetized by hypothermia and sacrificed by decapitation. Their eyes were enucleated and placed in Dulbecco's modified Eagle's medium: Nutrient mixture F12 (1:1; DMEM/F12, Gibco Co., Grand Island, NY). The retina from each eye was detached and isolated. Retinal cells were dissociated by combining 12 retinae with 5 ml of papain solution, containing 10 mg papain (34 units/ml; Sigma Chemical Co., St Louis, MO), 2 mg DL-cysteine (3.3 mM; Sigma, St. Louis, MO) and 2 mg bovine serum albumin (0.4 mg/ml; Sigma) in 5 ml of DMEM/F12, for 25 min at 37°C, then washed 3 times with 5 ml RGC medium (DMEM (Gibco), supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), 4 mM glutamine (Gibco), 100 units/ml penicillin and 100 µg/ml streptomycin (Sigma). Additional RGC medium was added to the retinal pieces to a final total volume of 40 ml. Retinal pieces were triturated by passing through a disposable pipette several times until cells were dispersed. Cell suspension (1.5 ml; containing

approximately 4.5×10^6 cells) was placed into each of the poly-D-lysine coated glass bottom culture dishes. The cells were cultured for 3 days in 95% air/5% CO₂ at 37°C.

Fetal calf serum was removed from the culture medium 3 days after the cells were isolated with or without various therapeutic agents. Three days later, the cells were observed with a fluorescent microscope at 200x magnification, and Di-I-labeled fluorescent cells in 20 microscopic fields were counted and averaged. The results are illustrated in Table 1, below:

Table 1: Effects of a neurotrophic factor stimulator on RGC survival

Cultured with Serum	Agent	RGC Survival (%)
Yes	None	100.0 ± 4.9*
No	None	46.4 ± 5.6
No	BDNF (5 µM) + Forskolin (10 ng/ml)	79.9 ± 5.4*
No	Propentofylline (100 µM)	96.9 ± 4.8*

Note: RGC survival in the presence of serum defines 100%. All values are expressed as mean and SEM (n=6). * represented $p < 0.05$ versus the no-serum, no-drug group by one-way ANOVA then Dunnett's test.

Table 1 illustrates that the survival of RGCs was greater in the presence of fetal calf serum (and the endogenous neurotrophic factors contained in the serum). The neurotrophic factor, BDNF, in the presence of forskolin, appeared to protect against such insult (i.e., removal of the fetal calf serum). Similarly, propentofylline, which is known to stimulate the production of nerve growth factor in cultured astrocytes (Shinoda et al., *Stimulation of nerve growth factor synthesis/secretion by propentofylline in cultured mouse astroglial cells*, Biochem. Pharmacol., volume 39, pages 1813-1816 (1990)) and in aged rat brain in vivo (Nabeshima et

al., *Impairment of learning and memory and the accessory symptom in aged rat as senile dementia model: oral administration of propentofylline produces recovery of reduced NGF content in the brain of aged rats*, Jpn. J. Psychol. Pharmacol., volume 13, pages 89-95 (1993)), also protected the cells against the serum deprivation-induced cell death. These data
5 indicate that compounds that stimulate neurotrophic factor production or increase their activity may protect retinal cells, especially RGCs, against injury induced by deprivation of neurotrophic factors.

The methods of the present invention comprise administering to a human patient one or more neurotrophic factor stimulators for the treatment of retinal or optic nerve head
10 neuropathy.

The methods of the present invention are particularly directed to the use of neurotrophin factor stimulators for the treatment of glaucoma, and other diseases and disorders of the outer retina, particularly age related macular degeneration, retinal ischemia, acute retinopathies associated with trauma, post-surgical complications, the damage
15 associated with laser therapy including photodynamic therapy (PDT), and surgical light induced iatrogenic retinopathy. As used herein, "retina or optic nerve head neuropathy" refers to any of the foregoing diseases or other retinal or optic nerve head neurodegenerative diseases.

The neurotrophic factor stimulators of the present invention may be contained in
20 various types of pharmaceutical compositions, in accordance with formulation techniques known to those skilled in the art. In general, the neurotrophic factor stimulators will be formulated in solutions or suspensions for topical ophthalmic or intraocular administration, or as tablets, capsules or solutions for systemic administration (e.g., oral or intravenous).

Oral formulations of the neurotrophin stimulators are preferred due to ease of administration. Oral formulations may be in liquid or solid form. In general, oral formulations will contain the active neurotrophin factor stimulator and inert excipients. In general, solid tablet or capsule dosages will contain various excipients such as bulking agents, binding agents, time release coatings, or other agents known to those skilled in the art. Liquid dosages will contain carriers, buffers, tonicity agents, solubilizing agents, or other agents known to those skilled in the art.

The compositions of the present invention may be administered intraocularly following traumatic and/or other acute ischemic events involving the retina and optic nerve head tissues or prior to or during surgery to prevent ischemic damage or injury. Compositions useful for intraocular administration will generally be intraocular injection compositions or surgical irrigating solutions. Intraocular injection compositions will generally be comprised of an aqueous solution, e.g., balanced salt irrigating solutions, discussed below.

When the neurotrophin factor stimulators are administered during intraocular surgical procedures, such as through retrobulbar or periocular injection and intraocular perfusion or injection, the use of balanced salt irrigating solutions as vehicles are most preferred. BSS® Sterile Irrigating Solution and BSS Plus® Sterile Intraocular Irrigating Solution (Alcon Laboratories, Inc., Fort Worth, Texas, USA) are examples of physiologically balanced intraocular irrigating solutions. The latter type of solution is described in United States Patent No. 4,550,022 (Garabedian et al.), the entire contents of which are incorporated herein by reference. Retrobulbar and periocular injections are known to those skilled in the art and are described in numerous publications including, for example, Ophthalmic Surgery: Principles of Practice, Ed., G.L. Spaeth, W.B. Sanders Co., Philadelphia, PA, U.S.A., pages 85-87 (1990).

In general, the doses utilized for the above described purposes will vary, but will be in an effective amount to prevent, reduce or ameliorate retina or optic nerve head neuropathy. As used herein, "pharmaceutically effective amount" refers to that amount of a neurotrophin factor stimulator which prevents, reduces or ameliorates retina or optic nerve head neuropathy. The neurotrophic factor stimulators will generally be contained in the topical or intraocular formulations contemplated herein in an amount of from about 0.001 to about 10.0% weight/volume ("%w/v"). Preferred concentrations will range from about 0.1 to about 5.0 % w/v. Topical formulations will generally be delivered to the eye one to six times a day, at the discretion of a skilled clinician. Systemic administration compositions will generally contain about 10-1000 mg of a neurotrophic factor stimulator, and can be taken 1-4 times per day, at the discretion of a skilled clinician.

As used herein, the term "pharmaceutically acceptable carrier" refers to any formulation which is safe, and provides the appropriate delivery of an effective amount of at least one neurotrophic factor stimulator for the desired route of administration.

The compositions of the present invention may contain additional pharmaceutically active agents or may be dosed concurrently with other pharmaceutical compositions. In particular, when treating a mammal for the prevention, treatment or amelioration of glaucomatous retinopathy, the compositions of the present invention may contain additional "anti-glaucoma" agents or may be dosed concurrently or sequentially with anti-glaucoma agent compositions. Examples of anti-glaucoma agents include: prostaglandins or prostanoids, carbonic anhydrase inhibitors, beta-adrenergic agonists and antagonists, alpha-adrenergic agonists or other anti-glaucoma agents known to those skilled in the art.

Example 2

Topical compositions useful for treating glaucomatous neuropathy:

Component	% (w/v)
AIT-082 (Neotrofin)	0.1-2.0
Tyloxapol	0.01-0.05
HPMC	0.5
Benzalkonium Chloride	0.01
Sodium Chloride	0.8
Edetate Disodium	0.01
NaOH/HCl	q.s. pH 7.4
Purified Water	q.s.

Example 3

A preferred topical composition useful for treating glaucomatous neuropathy:

Component	% (w/v)
AIT-082 (Neotrofin)	0.5-1.0
Tyloxapol	0.01-0.05
HPMC	0.5
Benzalkonium Chloride	0.01
Sodium Chloride	0.8
Edetate Disodium	0.01
NaOH/HCl	q.s. pH 7.4
Purified Water	q.s.

The above formulation is prepared by first placing a portion of the purified water into a beaker and heating to 90°C. The hydroxypropylmethylcellulose (HPMC) is then added to the heated water and mixed by means of vigorous vortex stirring until all of the HPMC is dispersed.

5 The resulting mixture is then allowed to cool while undergoing mixing in order to hydrate the HPMC. The resulting solution is then sterilized by means of autoclaving in a vessel having a liquid inlet and a hydrophobic, sterile air vent filter.

The sodium chloride and the edetate disodium are then added to a second portion of the purified water and dissolved. The benzalkonium chloride is then added to the solution, and the

10 pH of the solution is adjusted to 7.4 with 0.1M NaOH/HCl. The solution is then sterilized by means of filtration.

AIT-082 is sterilized by either dry heat or ethylene oxide. If ethylene oxide sterilization is selected, aeration for at least 72 hours at 50°C. is necessary. The sterilized compound is weighed aseptically and placed into a pressurized ballmill container. The tyloxapol, in sterilized

15 aqueous solution form, is then added to the ballmill container. Sterilized glass balls are then added to the container and the contents of the container are milled aseptically at 225 rpm for 16 hours, or until all particles are in the range of approximately 5 microns.

Under aseptic conditions, the micronized drug suspension formed by means of the preceding step is then poured into the HPMC solution with mixing. The ballmill container and

20 balls contained therein are then rinsed with a portion of the solution containing the sodium chloride, the edetate disodium and benzalkonium chloride. The rinse is then added aseptically to the HPMC solution. The final volume of the solution is then adjusted with purified water and, if necessary, the pH of the solution is adjusted to pH 7.4 with NaOH/HCl.

Example 4

Formulation for oral administration:

Tablet:

1-1000 mg of a neurotrophic factor stimulator with inactive ingredients such as starch, lactose and magnesium stearate can be formulated according to procedures known to those skilled in the art of tablet formulation.

Example 5

Preferred formulation for a topical ocular solution:

Component	% (w/v)
AIT-082 (Neotrofin)	0.5-1.0
Benzalkonium chloride	0.01
HPMC	0.5
Sodium chloride	0.8
Sodium phosphate	0.28
Edetate disodium	0.01
NaOH/HCl	q.s. pH 7.2
Purified Water	q.s.

Example 6

A preferred formulation for oral administration:

5 Tablet:

50-500 mg of AIT-082 (Neotrofin) with inactive ingredients such as starch, lactose and magnesium stearate can be formulated according to procedures known to those skilled in the art of tablet formulation.

10 The invention in its broader aspects is not limited to the specific details shown and described above. Departures may be made from such details within the scope of the accompanying claims without departing from the principles of the invention and without sacrificing its advantages.

I Claim:

1. A composition for the treatment of retina or optic nerve head neuropathy
5 comprising an effective amount of one or more neurotrophic factor stimulator(s) and a
pharmaceutically acceptable vehicle.

2. A composition according to Claim 1, wherein the neurotrophic factor
stimulator is selected from the group consisting of AIT-082 (neotrofin), idebenone, ONO-
10 2506, CB-1093, NS521 ((1-(1-butyl)-4-(2-oxo-1-benzimidazolone) piperidine, SS-701, KT-711
and clenbuterol.

3. A composition according to Claim 2, wherein the neurotrophic factor
stimulator is AIT-082 (neotrofin).
15

4. A composition according to Claim 1, wherein the composition is an oral
formulation.

5. A composition according to Claim 1, wherein the composition is a topical
20 ophthalmic, or intraocular formulation.

6. A composition according to Claim 3, wherein the composition is an oral
formulation.

7. A composition according to Claim 3, wherein the composition is a topical
25 ophthalmic, or intraocular formulation.

8. A method for the treatment of retina or optic nerve head neuropathy which
comprises administering to a mammal a composition comprising an effective amount of one
30 or more neurotrophic factor stimulator(s) and a pharmaceutically acceptable vehicle.

9. A method according to Claim 8, wherein the neurotrophic factor stimulator is selected from the group consisting of: AIT-082 (neotrofin), idebenone, ONO-2506, CB-1093, NS521 ((1-(1-butyl)-4-(2-oxo-1-benzimidazolone) piperidine, SS-701, KT-711 and clenbuterol..

5

10. A method according to Claim 9, wherein the neurotrophic factor stimulator is AIT-082 (neotrofin).

11. A method according to Claim 8, wherein the composition is an oral
10 formulation.

12. A method according to Claim 8, wherein the composition is a topical
ophthalmic, or intraocular formulation.

13. A method according to Claim 10, wherein the composition is an oral
15 formulation.

14. A method according to Claim 10, wherein the composition is a topical
ophthalmic, or intraocular formulation.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63) <input checked="" type="checkbox"/> Declaration Submitted with Initial Filing OR <input type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)	Attorney Docket Number	1719F US
	First Named Inventor	PANG
	COMPLETE IF KNOWN	
	Application Number	/ NYA
	Filing Date	May 25, 2001
	Group Art Unit	NYA
	Examiner Name	NYA

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

USE OF NEUROTROPHIC FACTOR STIMULATORS FOR THE TREATMENT OF OPTHALMIC NEURODEGENERATIVE DISEASES

the specification of which (Title of the Invention)

is attached hereto

OR

☒ was filed on (MM/DD/YYYY) 12.01.1999 as United States Application Number or PCT International

Application Number PCT/US99/28385 and was amended on (MM/DD/YYYY) NA (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	
60/110983	12.03.1998	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)
Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
PCT/US99/28385	12/01/1999	

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number

OR

☒ Registered practitioner(s) name/registration number listed below

Place Customer
Number Bar Code
Label here


Name	Registration Number	Name	Registration Number
ARNO, James A.	26,145	SHIRA, Jeffrey S.	34,922
BROWN, Gregg C.	30,613	RYAN, Patrick M.	36,263
YEAGER, Sally	32,757	LEE, W. David	39,743
COPELAND, Barry	34,801		

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto

Direct all correspondence to: ☒ Customer Number or Bar Code Label  OR ☐ Correspondence address below

Name	26356				
Address	PATENT TRADEMARK OFFICE				
Address					
City	State	ZIP			
Country	Telephone	(817) 551-4031	Fax	(817) 551-4610	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:		<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle if any)		Family Name or Surname			
Iok-hou		PANG			
Inventor's Signature				Date	5/25/01
Residence: City	Grand Prairie	State	TX	Country	US
Post Office Address	125 Starbridge Lane TX				
Post Office Address					
City	Grand Prairie	State	TX	ZIP	75052
				Country	US

Additional inventors are being named on the _____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto